CEO since 2018
Michael is a business oriented and flexible leader with extensive experience from the Life science and pharmaceutical industry. Michael has been working at KabiGen, Pharmacia and Pharmacia & UpJohn performing development of pharmaceuticals at different management levels. Michael has also been working in Business Development plus sales and marketing at Biovitrum (today Sobi) and as Marketing Director at APL (Apotek Produktion & Laboratorier). Prior to joining AroCell, Michael was CEO of Karessa Pharma, a Clinical stage pharma development company in Sweden. Has a M Sc.
Holdings in AroCell: 151 363 shares.
Warrants in AroCell: 400 000.
CFO since 2018
Anders Hultman started his employment at Arocell 2018. He has more than 15 years’ experience in managerial and executive positions within finance, sales, and marketing. Furthermore, he has extensive international experience from several executive positions such as CFO, Sales Director, Product Marketing Director, and CEO in pharma, IT, telecom, and e-commerce companies. He has also worked as a journalist at Reuters and founded several companies. Anders has a Bachelor of Science in Business Administration and Economics from Uppsala University.
Holdings in AroCell: 120 000 shares.
Warrants in AroCell: 300 000.
CSO since 2003
Staffan Eriksson has more than 35 years’ experience in medical biochemistry and cell biology with a PhD and an MD from the Karolinska Institute. He was appointed Professor in Medical and Physiological Chemistry at The Swedish University of Agricultural Sciences, Uppsala, in 1992. He has published more than 200 publications in peer-reviewed journals and supervised 15 doctoral students. Staffan is a leading scientist in the area of structure and function of Thymidine Kinase 1 with more than 100 publications during the last 10 years.
Staffan is one of the founders of AroCell and has served as CSO and Board Member of AroCell since 2003.
Holdings in AroCell: 422 450 shares.
Warrants in AroCell: 100 000.
Regulatory Affairs director since 2019
Peter Löwendahl has 30 years of experience working in regulatory affairs. He was previously responsible for quality and regulatory affairs at Elekta AB and globally responsible for regulatory affairs within GE Healthcare’s life science department. Peter Löwendahl has been working as a senior consultant and advisor for Hoff & Lowendahl AB since 2016.